Related Experiment Video
Updated: Feb 28, 2026

Auricular Point Acupressure Therapy: A Safe and Effective Treatment for Postsurgical Abortion Recovery
Published on: February 3, 2026
Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and
Abstract:
This article provides information on recent changes in the US Food and Drug Administration (FDA) labeling and safety regulations for mifepristone (Mifeprex). The revised label now permits midwives, advanced practice nurses, and physician assistants to order and prescribe mifepristone, eliminating the requirement for physician supervision. The updated label also extends eligibility for use from 49 to 70 days' gestation and decreases the number of required visits from 3 to 2. The recommended dose of mifepristone has been reduced, and the dosage, timing, and route of administration for misoprostol have also been changed to reflect current research. These changes have implications for clinical practice and may lead to expanded access for women in the United States.
More Related Videos
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
05:46Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
Related Concept Videos
Drug Regulation
Drug Products: Biologics, Biosimilars and Interchangeables
Intrauterine Drug Delivery Systems
FDA Approved Drugs: Changes to Approved Drugs
Drug Control Governance: Regulatory Bodies and Their Impact
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions